SI0801564T1 - Uporaba nebivolola kot antiaterogenskega sredstva - Google Patents
Uporaba nebivolola kot antiaterogenskega sredstvaInfo
- Publication number
- SI0801564T1 SI0801564T1 SI9530591T SI9530591T SI0801564T1 SI 0801564 T1 SI0801564 T1 SI 0801564T1 SI 9530591 T SI9530591 T SI 9530591T SI 9530591 T SI9530591 T SI 9530591T SI 0801564 T1 SI0801564 T1 SI 0801564T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alpha
- nebivolol
- atherogenic
- chromanmethanol
- iminobis
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title 1
- 230000000489 anti-atherogenic effect Effects 0.000 title 1
- 229960000619 nebivolol Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94203775 | 1994-12-28 | ||
| EP95942209A EP0801564B1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
| PCT/EP1995/005174 WO1996019987A1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI0801564T1 true SI0801564T1 (sl) | 2002-08-31 |
Family
ID=8217503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9530591T SI0801564T1 (sl) | 1994-12-28 | 1995-12-21 | Uporaba nebivolola kot antiaterogenskega sredstva |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US5874461A (sl) |
| EP (1) | EP0801564B1 (sl) |
| JP (1) | JPH10511655A (sl) |
| KR (1) | KR100264348B1 (sl) |
| CN (1) | CN1167418C (sl) |
| AT (1) | ATE214924T1 (sl) |
| AU (1) | AU700364B2 (sl) |
| CA (1) | CA2207333C (sl) |
| CZ (1) | CZ287513B6 (sl) |
| DE (1) | DE69526120T2 (sl) |
| DK (1) | DK0801564T3 (sl) |
| ES (1) | ES2176354T3 (sl) |
| FI (1) | FI118884B (sl) |
| HU (1) | HU226208B1 (sl) |
| NO (1) | NO315687B1 (sl) |
| NZ (1) | NZ298074A (sl) |
| PT (1) | PT801564E (sl) |
| SI (1) | SI0801564T1 (sl) |
| SK (1) | SK282144B6 (sl) |
| WO (1) | WO1996019987A1 (sl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0801564B1 (en) * | 1994-12-28 | 2002-03-27 | Janssen Pharmaceutica N.V. | Use of nebivolol as an anti-atherogenic |
| DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
| US6713651B1 (en) | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| JP2000207219A (ja) * | 1999-01-18 | 2000-07-28 | Fujitsu Ten Ltd | 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末 |
| US6593497B1 (en) | 1999-06-02 | 2003-07-15 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| JP2004528337A (ja) | 2001-05-02 | 2004-09-16 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化ネビボロール、ならびにその代謝産物、組成物、および使用方法 |
| EP1558922B1 (en) * | 2002-10-30 | 2013-02-27 | Ampere Life Sciences, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| ITTO20030140U1 (it) * | 2003-09-16 | 2005-03-17 | Interfila Srl | Matita cosmetica |
| US7470798B2 (en) | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| EP1737847B1 (en) | 2004-07-30 | 2008-06-04 | Torrent Pharmaceuticals Ltd | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol |
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| DK1888059T3 (en) | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP3018122B1 (en) | 2007-11-06 | 2018-10-10 | BioElectron Technology Corporation | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| US20090181975A1 (en) * | 2008-01-15 | 2009-07-16 | Forest Laboratories Holdings Limited | Nebivolol in the treatment of sexual dysfunction |
| JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| SG172275A1 (en) * | 2008-12-19 | 2011-07-28 | Schering Corp | Feed supplement for mammalian cell culture and methods of use |
| BRPI1013376A8 (pt) | 2009-04-28 | 2017-07-11 | Edison Pharmaceuticals Inc | Uso de quinonas de tocotrienol,preparação farmacêutica compreendendo as ditas quinonas e uso desta |
| CN103037839A (zh) * | 2010-06-04 | 2013-04-10 | 全球药物科技有限公司 | 含有矫味剂的口服美其敏水性制剂 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| DE102014107132A1 (de) | 2014-05-20 | 2015-11-26 | Corden Pharma International Gmbh | Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind |
| TW201615221A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 炎症用藥臨床新應用 |
| EP3233786B1 (en) | 2014-12-16 | 2022-03-16 | PTC Therapeutics, Inc. | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1337432C (en) * | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
| TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| EP0801564B1 (en) * | 1994-12-28 | 2002-03-27 | Janssen Pharmaceutica N.V. | Use of nebivolol as an anti-atherogenic |
-
1995
- 1995-12-21 EP EP95942209A patent/EP0801564B1/en not_active Expired - Lifetime
- 1995-12-21 DE DE69526120T patent/DE69526120T2/de not_active Expired - Lifetime
- 1995-12-21 SK SK856-97A patent/SK282144B6/sk not_active IP Right Cessation
- 1995-12-21 CN CNB951971492A patent/CN1167418C/zh not_active Expired - Lifetime
- 1995-12-21 PT PT95942209T patent/PT801564E/pt unknown
- 1995-12-21 AT AT95942209T patent/ATE214924T1/de active
- 1995-12-21 NZ NZ298074A patent/NZ298074A/xx not_active IP Right Cessation
- 1995-12-21 CA CA002207333A patent/CA2207333C/en not_active Expired - Fee Related
- 1995-12-21 HU HU9800675A patent/HU226208B1/hu unknown
- 1995-12-21 CZ CZ19971919A patent/CZ287513B6/cs not_active IP Right Cessation
- 1995-12-21 KR KR1019970703648A patent/KR100264348B1/ko not_active IP Right Cessation
- 1995-12-21 AU AU43477/96A patent/AU700364B2/en not_active Expired
- 1995-12-21 DK DK95942209T patent/DK0801564T3/da active
- 1995-12-21 ES ES95942209T patent/ES2176354T3/es not_active Expired - Lifetime
- 1995-12-21 WO PCT/EP1995/005174 patent/WO1996019987A1/en active IP Right Grant
- 1995-12-21 US US08/860,238 patent/US5874461A/en not_active Expired - Lifetime
- 1995-12-21 SI SI9530591T patent/SI0801564T1/sl unknown
- 1995-12-21 JP JP8520223A patent/JPH10511655A/ja active Pending
-
1997
- 1997-06-26 NO NO19972980A patent/NO315687B1/no not_active IP Right Cessation
- 1997-06-27 FI FI972793A patent/FI118884B/fi not_active IP Right Cessation
-
1998
- 1998-12-21 US US09/217,728 patent/US6075046A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996019987A1 (en) | 1996-07-04 |
| US5874461A (en) | 1999-02-23 |
| US6075046A (en) | 2000-06-13 |
| CN1167418C (zh) | 2004-09-22 |
| SK85697A3 (en) | 2000-04-10 |
| EP0801564A1 (en) | 1997-10-22 |
| CZ191997A3 (cs) | 1999-01-13 |
| ES2176354T3 (es) | 2002-12-01 |
| MX9704669A (es) | 1997-09-30 |
| CN1171739A (zh) | 1998-01-28 |
| DK0801564T3 (da) | 2002-07-15 |
| NO972980D0 (no) | 1997-06-26 |
| EP0801564B1 (en) | 2002-03-27 |
| NO315687B1 (no) | 2003-10-13 |
| DE69526120T2 (de) | 2002-11-28 |
| ATE214924T1 (de) | 2002-04-15 |
| NZ298074A (en) | 2001-01-26 |
| NO972980L (no) | 1997-06-26 |
| CZ287513B6 (en) | 2000-12-13 |
| KR100264348B1 (ko) | 2000-08-16 |
| CA2207333A1 (en) | 1996-07-04 |
| CA2207333C (en) | 2006-10-17 |
| JPH10511655A (ja) | 1998-11-10 |
| SK282144B6 (sk) | 2001-11-06 |
| HU226208B1 (en) | 2008-06-30 |
| DE69526120D1 (de) | 2002-05-02 |
| FI972793A (fi) | 1997-06-27 |
| HUT77927A (hu) | 1998-11-30 |
| FI118884B (fi) | 2008-04-30 |
| FI972793A0 (fi) | 1997-06-27 |
| AU4347796A (en) | 1996-07-19 |
| AU700364B2 (en) | 1999-01-07 |
| PT801564E (pt) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI0801564T1 (sl) | Uporaba nebivolola kot antiaterogenskega sredstva | |
| CA2272584A1 (en) | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | |
| BG107537A (en) | Method for the inhibition of human tnf alpha activity and its application | |
| BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
| HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
| EP0923376A4 (en) | TREATMENT OF ASTHMA AND RESPIRATORY DISEASES | |
| AU2549797A (en) | Xanthone analogs for the treatment of infectious diseases | |
| IL110943A (en) | Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| ATE231849T1 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
| BG105275A (en) | Tan-1057 derivatives | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| BG102707A (en) | New triazolopurinpurines, method for their preparation and appplication as medicamentous forms | |
| BG102667A (en) | Diosgenine-containing composition | |
| MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
| IL143382A0 (en) | Human adult astrocytes, their preparation and uses thereof | |
| MD970254A (en) | Use of melatonine for treatment of patients having a medicamental dependence | |
| AU1278600A (en) | Novel therapeutic application of nicergoline | |
| AU2392797A (en) | Use of benzonaphthalene derivatives for the manufacture of medicaments for the treatment of diseases of the nervous system | |
| AU1569700A (en) | Novel therapeutic application of low molecular weight heparin | |
| NZ302670A (en) | Use of 2,3-dihydro-imidazo[2,1-b]benzothiazole derivatives to treat degenerative disorders and ageing of the nervous and vascular systems | |
| WO1999021538A3 (de) | Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten | |
| AU1278700A (en) | Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline | |
| MX9706931A (es) | Derivados de amida de acido-2-ciano-3,5-dihidroxi-hex-2-eno-carboxilico. | |
| BG102864A (en) | Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions |